Brain 17 Vienna

PROFILE trials

ALK+ advanced NSCLC & brain metastases

PROFILE 1005

PROFILE 1007

Phase II

randomise

730 patients

158 patients

Crizotinib

Crizotinib

chemotherapy

888 patients

brain metastases

no brain metastases

613 patients

275 patients

Brain metastases in patients with ALK-positive NSCLC

Costa et al 2015, J Clin Oncol; 33 (17): 1881-1888